Pharmacist Digest

STAT+: RaDonda Vaught, nurse who accidentally killed patient, to speak at CommonSpirit event on patient safety

STAT

MARCH 1, 2024

CommonSpirit Health is hosting an educational event this month featuring RaDonda Vaught, the Tennessee nurse who was criminally prosecuted for accidentally killing a patient by injecting the wrong medication. The session, held during National Patient Safety Week, will cover medical error prevention and “systems thinking.”

Hospitals

Opinion: Health care providers need help to treat patients during extreme heat events

STAT

OCTOBER 31, 2023

The world’s hottest summer on record is now bleeding into the fall. Instead of enjoying a cool respite from the heat, millions of Americans started September enduring temperatures so high that schools were forced to close across the country.

DIA 2023 – a “patients included” global event

pharmaphorum

JUNE 29, 2023

DIA 2023 – a “patients included” global event Mike.Hammerton Thu, 29/06/2023 - 08:00 Bookmark this

STAT+: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition

STAT

APRIL 28, 2024

Physicians involved with MorphoSys’ completed Phase 3 study have reported multiple cases of palebresib-treated patients who rapidly progressed from myelofibrosis, a cancer affecting the bone marrow, to acute myeloid leukemia, a more aggressive and deadlier type of blood cancer, according to two people with knowledge of the cases.

STAT+: Eli Lilly’s Zepbound eases obstructive sleep apnea in trials

STAT

APRIL 17, 2024

In one year-long Phase 3 study that looked at patients with obesity who were not on PAP therapy, a form of ventilation, those taking Zepbound experienced a reduction of 25.3 events per hour on the apnea-hypopnea index (AHI), a measure of the number of times breathing stops and becomes restricted while sleeping.

Adverse Event Reporting: Patients Flock to Social Media

PharmExec

APRIL 19, 2023

In this exclusive Q&A, Marie Flanagan, offering management director, IQVIA, reveals how patients are reporting adverse events in large numbers on social media.

STAT+: Getting Alzheimer’s treatment to those who need it poses particular challenges

STAT

MAY 9, 2024

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Medical Schools

Niacin has long been a public health darling. But an excess could be bad for the heart, study suggests

STAT

FEBRUARY 19, 2024

The study looked into two cohorts of patients without active heart disease, 60% of whom were treated with statins, and found a strong association between a metabolic product of excess niacin and an increased risk of major adverse cardiovascular events such as a heart attack or stroke. Read the rest…

Diabetes

STAT Virtual Event | Navigating a New Era in Alzheimer’s Treatment

STAT

MAY 7, 2024

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Now patients and physicians face a new challenge: actually getting the medicines to people who might benefit from them. It took decades for scientists to come up with treatments that could slow the progression of Alzheimer’s disease.

STAT+: Novo Nordisk’s diabetes drug Ozempic cuts risk of kidney disease progression, trial shows

STAT

MARCH 5, 2024

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes. and Europe.

Diabetes

Finerenone May Protect Patients With Chronic Kidney Disease From Pneumonia-Related Severe Adverse Events

Pharmacy Times

NOVEMBER 2, 2022

The drug is a selective, nonsteroidal mineralocorticoid receptor antagonist found to also protect against COVID-19 and pneumonia-related adverse events in patients with diabetes.

Diabetes

STAT+: Nvidia says generative AI will revolutionize health care. So did IBM, with Dr. Watson

STAT

MARCH 25, 2024

It was slow to use computers, digitize patient data, and share information electronically. The health care sector is a notorious laggard when it comes to technology. While most of the world instantly interacts via Zoom and Slack, hospitals — even today — are still sending faxes. last week.

Hospitals

Virtual Event: March of the Biosimilars

STAT

MARCH 14, 2024

Editor’s note: A livestream of this event will be embedded below at 1 p.m. Join leading experts to discuss the impact on the industry and patients. Join leading experts to discuss the impact on the industry and patients. market over the past year.

Biosimilars

STAT Virtual Event | Cancer’s Breakthrough Engine

STAT

DECEMBER 18, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Since the development of Gleevec two decades ago, precision cancer medicines have become a driving force in biotech and a source of hope for cancer patients. Read the rest…

Rare diseases, very special patients highlighted in event

Outsourcing Pharma

FEBRUARY 28, 2022

The recent Outsourcing-Pharma webinar hosted a trio of industry experts highlighting challenges, opportunities, and innovations in the rare disease realm.

STAT+: Anthos stroke drug appears safer than common blood thinner in mid-stage trial

STAT

NOVEMBER 12, 2023

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients. Continue to STAT+ to read the full story…

Virtual Event: Can Tech Fix Primary Care?

STAT

MARCH 20, 2023

Editor’s note: A livestream on the event will be embedded below at 1 p.m. Patients are having a difficult time seeing doctors quickly and understanding what specialists they can see. Physicians are burned out and overworked. Read the rest…

STAT+: Vertex’s closely-watched pain relief drug succeeds in late-stage trials — with a catch

STAT

JANUARY 30, 2024

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. Continue to STAT+ to read the full story…

Drug Development

STAT+: Vertex pain drug results met with measured optimism — and questions — by observers and experts

STAT

JANUARY 30, 2024

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint.

Drug Development

STAT Virtual Event: The Next Frontier of Drug Pricing Reform

STAT

JUNE 21, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m. But does the system work for patients? Pharmacy benefit managers are intermediaries that are supposed to negotiate lower drug costs. And how can we fix it when it doesn’t? Read the rest…

Drug Pricing

Opdivo plus chemo improves event-free survival in NSCLC patients

Pharma Times

NOVEMBER 8, 2021

Detailed results from the CheckMate-816 trial will be shared at an upcoming medical conference

These blood-clot catching devices have been controversial for years. Why are doctors still relying on them?

STAT

FEBRUARY 2, 2023

But for over a decade, these devices have been dogged by questions about how well they work and the serious complications they can cause for patients. Read the rest…

STAT+: Death of patient in closely watched Alzheimer’s trial raises concern about risk for some groups

STAT

OCTOBER 28, 2022

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned. Continue to STAT+ to read the full story…

Documentation

Documentation Drug Development

Patients With CKD, Hyperkalemia Have Higher Rates of Major Adverse Cardiovascular Events

Pharmacy Times

NOVEMBER 2, 2023

An analysis of the REVOLUTIONIZE II study data showed that there is an unmet need for long-term outpatient treatment of hyperkalemia in patients with CKD.

Opinion: Every smartphone should have an app to connect to 988, the mental health crisis line

STAT

SEPTEMBER 22, 2023

At the height of the pandemic, when everything was shut down, a patient with whom I had a long-term relationship developed suicidal ideation. The good news was that I could still have used this bricked phone to call 911 in the event of an emergency. And he was ashamed to use his parents’ telephone because of privacy issues.

STAT+: Mirum’s Chenodal succeeds in late-stage trial for rare metabolic disorder

STAT

OCTOBER 2, 2023

The results potentially pave the way for the treatment, already used by physicians, to reach a wider pool of patients. In the Phase 3 study, dubbed RESTORE, 13 participants all started off on the drug, known as Chenodal, an oral tablet that contains a bile acid patients don’t make enough of.

Drug Development

STAT+: CRO claims there was no misconduct in Lyme vaccine trial it ran for Pfizer

STAT

OCTOBER 11, 2023

Care Access served as a contract research organization and had enrolled about 3,000 patients in the late-stage trial. Pfizer and Valneva maintained there were no safety issues or adverse events prompting the decision, and instead blamed unspecified problems with the conduct of the study.

Vaccines

Dobbs decision leaving broad imprint on reproductive medicine

STAT

OCTOBER 20, 2023

This year’s event still bore the familiar trappings of hope — 8-foot-high photos of parents holding newborns bathed in rays of sunshine, a verdant “wishing wall” bedecked with crepe-paper flowers crumpled around wishes made on behalf of patients experiencing infertility.

STAT Virtual Event – Decoding Clinical Trials: How to Spot and Avoid Clinical Trial Risk

STAT

JUNE 9, 2023

Editor’s Note: A livestream of the event will be embedded below on Monday, June 12 at 1 p.m. ET Running a successful clinical trial is as much about execution as science, as companies and researchers must nail operational details from picking the right trial sites to ensuring patients remain in the study.

STAT+: Hospitals offer their custom-built tech for sale in search of new revenue streams

STAT

JANUARY 19, 2024

But that’s changing thanks to a collision of financial pressures and an explosion of new technology that could both improve patients’ health and ease the burden of administrative tasks on limited staff. At the J.P.

Hospitals

Hospitals Mayo Clinic

Vascepa reduces ischemic events in heart attack patients, trial finds

Pharma Times

AUGUST 24, 2021

Data presented at ESC Congress 2021

STAT+: Late-stage trial supports broader use of Darzalex, blockbuster J&J multiple myeloma drug

STAT

DECEMBER 12, 2023

In the Phase 3 trial, known as Perseus, newly diagnosed patients about to receive an infusion of their own blood stem cells were randomly assigned a standard three-drug treatment or the same cocktail with the addition of Darzalex. Continue to STAT+ to read the full story…

Immunity

Immunity Immunization

How a Black veteran desegregated a Texas medical school

STAT

FEBRUARY 14, 2023

These are important events that changed the course of medicine, but they’re also examples in which Black people were unknowingly harmed as patients. Vanessa Northington Gamble, a physician and researcher at George Washington University, wants us to know more stories of Black people actively resisting racism within medicine.

Medical Schools

2024 Washington Representatives Retreat

Putting Patients First Blog

MAY 7, 2024

2024 Washington Representatives Retreat Event Time: 9:30 a.m. ET - 1:45 p.m. The post 2024 Washington Representatives Retreat appeared first on National Health Council.

STAT+: The biotech scorecard for the first quarter: 19 stock-moving events to watch

STAT

JANUARY 3, 2023

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Last year, a novel combination pill developed by Karuna Therapeutics reduced psychosis and related symptoms experienced by patients with schizophrenia, achieving the main goals of a late-stage clinical trial.

As wildfires burn, scientists race to understand the health dangers of prolonged exposure

STAT

JULY 31, 2023

The hazy conditions, fed by an unprecedented surge in Canadian wildfires likely fueled by climate change, has grounded planes, canceled outdoor sporting events, and filled emergency rooms with asthma patients.

Pharmacy closures 'could double' without action, contractors warn

The Pharmacist

MARCH 21, 2024

Pharmacy closures are a 'worry' for patients and could 'double' if action is not taken to prevent them, community pharmacy representatives have said as they gathered outside the Houses of Parliament yesterday before meeting with MPs.

Community Pharmacies

STAT+: What to expect from hospitals and health insurers at this year’s JPM Healthcare Conference

STAT

JANUARY 7, 2024

And similar to last year , when hospitals touted their plans for expansion and hiking prices, they will have a rosy picture to sell to financiers as patients flock to their facilities. STAT spoke with attorneys, analysts, and health care executives who are attending JPM’s event or are watching from afar.

Hospitals

STAT+: Trailing other sickle cell drug makers, Editas still sees opportunity for its CRISPR therapy

STAT

JUNE 9, 2023

On Friday, Editas offered a preliminary update on the handful of patients who’ve received its gene-editing-based therapy for sickle cell, which is also being tested for another blood disorder, beta thalassemia. Continue to STAT+ to read the full story…

Drug Development

‘What’s next for patient advocacy?’ Senior leader speakers for Patient Partnership Index event announced

Pharma Times

JUNE 24, 2021

‘What’s next for patient advocacy?’ ’ will take place on Tuesday 6th July at 8.30am

STAT+: The biotech scorecard for the fourth quarter: 14 stock-moving events to watch

STAT

SEPTEMBER 30, 2022

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter: Arrowhead Pharmaceuticals and partner Takeda Pharmaceuticals are nearing the completion of a mid-stage, placebo-controlled clinical trial of an RNA-based drug called fazirsiran in patients with alpha-1 antitrypsin deficiency, or AATD, (..)

Results show potential of J&J’s TAR-210 to transform treatment of bladder cancer with FGFR alterations

Express Pharma

MAY 5, 2024

2,3 At the data cutoff of March 22, 2024, 64 patients had been treated with TAR-210 across the two cohorts. 2,3 At the data cutoff of March 22, 2024, 64 patients had been treated with TAR-210 across the two cohorts. 1 The most common treatment-related emergent adverse events (TEAEs) were Grade 1/2 lower urinary tract events.

Labelling

‘What’s next for patient advocacy?’ Leaders share lessons of Patient Partnership Index 2021 at free virtual event

Pharma Times

JULY 7, 2021

During the event, the panel explored how partnerships innovated in the face of challenges

‘I question what I know’: Top cancer specialist Otis Brawley on valuing orthodoxy in medicine

STAT

DECEMBER 7, 2022

Now, he says, advances in cancer treatments and early-detection screenings are fast outpacing the medical community’s ability to assess them — warranting more caution lest doctors inadvertently cause more harm to cancer patients. Read the rest…

STAT+: RaDonda Vaught, nurse who accidentally killed patient, to speak at CommonSpirit event on patient safety

Opinion: Health care providers need help to treat patients during extreme heat events

Trending Sources

DIA 2023 – a “patients included” global event

STAT+: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition

STAT+: Eli Lilly’s Zepbound eases obstructive sleep apnea in trials

Adverse Event Reporting: Patients Flock to Social Media

STAT+: Getting Alzheimer’s treatment to those who need it poses particular challenges

Niacin has long been a public health darling. But an excess could be bad for the heart, study suggests

STAT Virtual Event | Navigating a New Era in Alzheimer’s Treatment

STAT+: Novo Nordisk’s diabetes drug Ozempic cuts risk of kidney disease progression, trial shows

Finerenone May Protect Patients With Chronic Kidney Disease From Pneumonia-Related Severe Adverse Events

STAT+: Nvidia says generative AI will revolutionize health care. So did IBM, with Dr. Watson

Virtual Event: March of the Biosimilars

STAT Virtual Event | Cancer’s Breakthrough Engine

Rare diseases, very special patients highlighted in event

STAT+: Anthos stroke drug appears safer than common blood thinner in mid-stage trial

Virtual Event: Can Tech Fix Primary Care?

STAT+: Vertex’s closely-watched pain relief drug succeeds in late-stage trials — with a catch

STAT+: Vertex pain drug results met with measured optimism — and questions — by observers and experts

STAT Virtual Event: The Next Frontier of Drug Pricing Reform

Opdivo plus chemo improves event-free survival in NSCLC patients

These blood-clot catching devices have been controversial for years. Why are doctors still relying on them?

STAT+: Death of patient in closely watched Alzheimer’s trial raises concern about risk for some groups

Patients With CKD, Hyperkalemia Have Higher Rates of Major Adverse Cardiovascular Events

Opinion: Every smartphone should have an app to connect to 988, the mental health crisis line

STAT+: Mirum’s Chenodal succeeds in late-stage trial for rare metabolic disorder

STAT+: CRO claims there was no misconduct in Lyme vaccine trial it ran for Pfizer

Dobbs decision leaving broad imprint on reproductive medicine

STAT Virtual Event – Decoding Clinical Trials: How to Spot and Avoid Clinical Trial Risk

STAT+: Hospitals offer their custom-built tech for sale in search of new revenue streams

Vascepa reduces ischemic events in heart attack patients, trial finds

STAT+: Late-stage trial supports broader use of Darzalex, blockbuster J&J multiple myeloma drug

How a Black veteran desegregated a Texas medical school

2024 Washington Representatives Retreat

STAT+: The biotech scorecard for the first quarter: 19 stock-moving events to watch

As wildfires burn, scientists race to understand the health dangers of prolonged exposure

Pharmacy closures 'could double' without action, contractors warn

STAT+: What to expect from hospitals and health insurers at this year’s JPM Healthcare Conference

STAT+: Trailing other sickle cell drug makers, Editas still sees opportunity for its CRISPR therapy

‘What’s next for patient advocacy?’ Senior leader speakers for Patient Partnership Index event announced

STAT+: The biotech scorecard for the fourth quarter: 14 stock-moving events to watch

Results show potential of J&J’s TAR-210 to transform treatment of bladder cancer with FGFR alterations

‘What’s next for patient advocacy?’ Leaders share lessons of Patient Partnership Index 2021 at free virtual event

‘I question what I know’: Top cancer specialist Otis Brawley on valuing orthodoxy in medicine

Stay Connected